Health Care • Biotechnology: Commercial Physical & Biological Resarch
$275.06 ▼ -3.98
(-1.43%)
MKT CAP: $45.33B • VOL: 1.43M
52W L $155 52W H $285
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$231
MEDIAN
$308
MEAN
$314
HIGH
$374
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IQV TAPE
IQV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $332.82 | $316.32 | 2025-02-14 | $250.30 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $346.58 | $324.57 | 2025-02-06 | $258.56 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $313.57 | $302.57 | 2025-01-29 | $264.06 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $280.56 | — | 2025-01-17 | $269.56 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $242.05 | $261.31 | 2025-01-09 | $244.80 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $327.32 | $286.06 | 2024-12-18 | $239.30 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $266.81 | $277.81 | 2024-12-04 | $255.81 | -4.3% | 48% | C |